Healthcare Industry News: drug-eluting stent
News Release - September 24, 2008
TransEnterix Inc. Names Experienced Medical Device Executive Todd M. Pope as President, CEORESEARCH TRIANGLE PARK, N.C., Sept. 24 (HSMN NewsFeed) -- TransEnterix, an early-stage, privately-held medical device company focused on advanced minimally invasive surgery, announced today that the Board of Directors has named Todd M. Pope the Company's first President and Chief Executive Officer. Mr. Pope has spent nearly 20 years in the medical device market with experience in cardiovascular, peripheral vascular, neurovascular, and laparoscopic surgery.
Mr. Pope, 43, was most recently the Worldwide President of Cordis, a multibillion dollar franchise within Johnson and Johnson's medical device sector.
"TransEnterix has made rapid and substantial progress since securing its first institutional financing this past December," said Fred McCoy, Chairman of the Board. "Now preparing to enter the extensive minimally-invasive surgery market, which is expected to be an $8 billion global market in 2008, it is essential to have seasoned and successful CEO leadership. Todd Pope is just such a leader."
Mr. Pope spent a total of 10 years at various leadership positions at Johnson and Johnson and Boston Scientific before joining TransEnterix.
"It has been my good fortune to have participated in two of the most significant growth revolutions in medical devices with laparoscopic surgery in the 1990s and drug-eluting stents in the early 2000s," Mr. Pope said. "We believe our company is poised to experience tremendous growth for years to come and I am excited to have the opportunity to lead TransEnterix from its earliest stages."
Mr. Pope is a Raleigh native and a graduate of the University of North Carolina at Chapel Hill. He and his family currently reside in Chapel Hill, NC.
TransEnterix, Inc. was founded in 2006 and in December, 2007, secured $21 million in its first round of institutional financing. The company is rapidly developing single port and NOTES (Natural Orifice Translumenal Endoscopic Surgery) product platforms for procedures that currently use traditional laparoscopic approaches.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.